Asston Pharmaceuticals Ltd (544445) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544445 | NSE: | Pharmaceuticals & Drugs | Small Cap

Asston Pharma Share Price

95 -0.13 -0.14%
as on 05-Dec'25 12:12

Asston Pharmaceuticals Ltd (544445) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544445 | NSE: | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Asston Pharma

Based on:

M-Cap below 100cr DeciZen not available

Asston Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
18.72
Market Cap:
81 Cr.
52-wk low:
75.2
52-wk high:
126

Is Asston Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Asston Pharmaceuticals Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Asston Pharmaceuticals Ltd is a below average quality company.

2. Is Asston Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Asston Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Asston Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Asston Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Asston Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Asston Pharmaceuticals Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 14%37.2%26.9%42.6%-
Value Creation
Index
-01.70.92.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 9.66.515.62525
Sales YoY Gr.--31.9%138.4%60.6%-
Adj EPS -0.71.337.15.1
YoY Gr.-NA140%136.7%-
BVPS (₹) 1.73.610.217.145
Adj Net
Profit
-0.40.71.94.54
Cash Flow from Ops. -1.2-0.3-3.8-0.2-
Debt/CF from Ops. -2.8-16.6-1.8-44.6-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA37.7%60.6%
Adj EPS NANANA136.7%
BVPSNANA117.5%67.7%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-44.24844.95216.4
Op. Profit
Mgn %
-3.723.221.125.5NAN
Net Profit
Mgn %
-4.310.712.117.817.3
Debt to
Equity
3.62.61.10.7-
Working Cap
Days
05833703360
Cash Conv.
Cycle
01051541780

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 37.65%

Debt to equity has declined versus last 3 years average to 0.68

Return on Equity has declined versus last 3 years average to 16.40%

Net Profit has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Asston Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 5.1 -
TTM Sales (₹ Cr.) 25 -
BVPS (₹.) 45 -
Reserves (₹ Cr.) 30 -
P/BV 2.12 -
PE 18.72 -
From the Market
52 Week Low / High (₹) 75.21 / 126.00
All Time Low / High (₹) 75.21 / 126.00
Market Cap (₹ Cr.) 81
Equity (₹ Cr.) 8.5
Face Value (₹) 10
Industry PE 40.7

Management X-Ray of Asston Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Asston Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Asston Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Sales9.606.5415.5925.04
Operating Expenses 9.955.0213.0418.88
Manufacturing Costs1.040.751.591.22
Material Costs6.702.688.2811.18
Employee Cost 0.260.230.280.90
Other Costs 1.951.362.895.58
Operating Profit -0.361.522.556.16
Operating Profit Margin (%) -3.7%23.2%16.3%24.6%
Other Income 0.960.650.250.57
Interest 0.430.720.930.95
Depreciation 0.010.040.050.08
Exceptional Items 0000
Profit Before Tax 0.161.411.825.70
Tax 0.050.360.461.37
Profit After Tax 0.111.061.364.33
PAT Margin (%) 1.2%16.2%8.7%17.3%
Adjusted EPS (₹)0.21.92.26.9
Dividend Payout Ratio (%)0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 0.931.996.3910.72
Share Capital 0.700.700.786.27
Reserves 0.231.295.614.45
Minority Interest0000
Debt3.254.956.185.99
Long Term Debt0.941.821.632.26
Short Term Debt2.313.134.553.73
Trade Payables4.535.545.815.86
Others Liabilities 0.781.221.885.53
Total Liabilities 9.4913.6920.2628.10

Fixed Assets

Gross Block0.941.191.201.10
Accumulated Depreciation0.030.060.110.14
Net Fixed Assets 0.921.131.090.96
CWIP 0000
Investments 0000
Inventories0.501.501.440.72
Trade Receivables6.408.6116.1524.55
Cash Equivalents 0.140.120.010.20
Others Assets 1.532.331.571.68
Total Assets 9.4913.6920.2628.10

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -1.19-0.32-3.80-0.16
PBT 0.161.411.825.70
Adjustment 0.440.750.940.93
Changes in Working Capital -1.76-2.46-6.11-6.79
Tax Paid -0.03-0.01-0.450
Cash Flow From Investing Activity -0-0.91-0.010.87
Capex -0-0.25-0.010.11
Net Investments 0-0.67-0.040.71
Others 00.010.040.05
Cash Flow From Financing Activity 1.291.213.69-0.51
Net Proceeds from Shares 0.6903.050
Net Proceeds from Borrowing -1.330.88-0.190.63
Interest Paid -0.43-0.72-0.93-0.95
Dividend Paid 0000
Others 2.371.061.77-0.19
Net Cash Flow 0.10-0.01-0.120.19

Finance Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)11.972.4932.4750.56
ROCE (%)13.9737.226.942.64
Asset Turnover Ratio1.010.560.921.04
PAT to CFO Conversion(x)-10.82-0.3-2.79-0.04
Working Capital Days
Receivable Days243419290297
Inventory Days19563416
Payable Days247685250191

Asston Pharmaceuticals Ltd Stock News

Asston Pharmaceuticals Ltd FAQs

The current trading price of Asston Pharma on 05-Dec-2025 12:12 is ₹95.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Asston Pharma stood at ₹80.98.
The latest P/E ratio of Asston Pharma as of 04-Dec-2025 is 18.72.
The latest P/B ratio of Asston Pharma as of 04-Dec-2025 is 2.12.
The 52-week high of Asston Pharma is ₹126.0 and the 52-week low is ₹75.21.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Asston Pharma is ₹25.04 ( Cr.) .

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was originally incorporated as ‘Asston Pharmaceuticals Private Limited’, a private limited company under Companies Act, 2013, pursuant to a certificate of incorporation dated April 16, 2019 issued by Registrar of Companies, Mumbai, Maharashtra. Thereafter, the company was converted into a public limited company and the name of the company was changed from ‘Asston Pharmaceuticals Private Limited’ to ‘Asston Pharmaceuticals Limited’ vide fresh certificate of incorporation dated August 29, 2024 issued by the Registrar of Companies, Mumbai, Maharashtra.

The company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. The company operates under brand ‘Asston’. The company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc. Apart from manufacturing products for direct sales, the company also manufactures various pharmaceutical products for different marketers on loan license or on contract manufacturing basis. Its business is primarily conducted on a principle-to-principle basis with various marketers.

It caters to multiple corporate clients on loan licence and/or contract manufacturing basis. The company basically gives contract for manufacturing the products to WHO-GMP certified contract manufacturers and FDA-accredited laboratories, ensuring adherence to industry standards from production to export. From manufacturing to exports and distributions, the company takes responsibility and oversees each phase of the supply chain.

Business area of the company

The company is engaged in the business of manufacturing pharmaceutical products.

Products of the company

Tablets

  • Albendazole USP 400 mg
  • KJFEN-50
  • Mebenex
  • Recomax
  • Ovcyst
  • Max- Relief
  • B-complex tablets

Capsules

  • Diclofenac 100 mg
  • Solocam
  • Omeprazole Capsules
  • All Cold
  • Medart Forte
  • Ampicloxa 500
  • Singatone Forte

Oral Suspension and Syrup and Creams

  • Ibuprofen, paracetamol
  • Ferrovit Syrup
  • Asstofer
  • Gripe Water
  • Folirex Forte Syrup
  • Clotrimazole Cream USP 1 % w/v
  • B-complex syrup

History and milestones

  • 2019: Incorporation of the Company viz. ‘Asston Pharmaceuticals Private Limited’ under the guidance and leadership of Dr. Ashish Narayan Sakalkar and Mrs. Saili Jayaram More.
  • 2019: The company obtained Trade and Export Licenses for 3 major west African Countries namely Sierra Leone, Ghana and Liberia.
  • 2020: The company obtained registered trademarks in both India and abroad for multiple products, enhancing its images as a pharmaceutical brand in late 2020.
  • 2021: The company crossed Rs 10 crore turnover mark in 2021, less than two years since inception.
  • 2022: Established its Manufacturing unit in Mumbai which is one of the company’s achievement making it an independent and reliable supplier.
  • 2023: The company has successfully ventured into other African countries and is expected to receive registration from Asian markets like Cambodia and Vietnam.
  • 2024: Conversion of the company from Private Limited to Public Limited Company.

You have 1 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×